Imagion Biosystems receives $300K order for supply of nanoparticles

Nov 27, 2019
Posted in: News, Investor updates

Home » Imagion Biosystems receives $300K order for supply of nanoparticles

Imagion Biosystems receives $300K order for supply of nanoparticles

Nov 27, 2019
Posted in: News, Investor updates

Imagion Biosystems Limited announced the NewPhase Ltd., an Israeli biotechnology company developing cancer treatments, has placed an order totaling approximately $300k for the supply of Imagion’s proprietary nanoparticles for 2020 to be used in the NewPhase product.
Read the announcement.

Imagion Biosystems HER2 Breast Cancer Program Update

October 7, 2025

Key Highlights: Manufacturing of the MagSense® HER2 Breast Cancer Imaging Agent for the Phase 2 clinical trial has been completed – major milestone achieved IBX,

Imagion Biosystems EGM Chairman’s Address

September 24, 2025

Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes through the early detection of cancer utilizing its proprietary MagSense® imaging

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

September 9, 2025

Highlights Dr Nina Webster appointed as IBX Non-Executive Director, bringing significant clinical development expertise and corporate experienceto the IBX Board ahead of HER2 Breast cancer

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Imagion Biosystems receives $300K order for supply of nanoparticles

Imagion Biosystems receives $300K order for supply of nanoparticles

Related Articles

Imagion Biosystems HER2 Breast Cancer Program Update

Imagion Biosystems EGM Chairman’s Address

Phase 2 HER2 Clinical Trial Manufacturing Commenced, WSU Imaging Optimisation Program Underway

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list